Sub-conjunctival and intraocular hemorrhages of various origins. Angioretinopathy (including diabetic retinopathy). Central and peripheral chorioretinal dystrophy. Thrombosis of the Central retinal vein and its branches. Complicated myopia. Angiosclerosis-related macular degeneration (dry form). Detachment of the vascular membrane in patients with glaucoma in the postoperative period. Dystrophic diseases of the cornea. Trauma, burns of the cornea. Protection of the cornea (when using contact lenses) and the retina from exposure to high-intensity light (sunlight, laser radiation during laser coagulation).
active substance: methylethylpyridinol hydrochloride;
1 ml of solution contains methyl ethylpyridinol hydrochloride 10 mg;
Emoxipin Excipients: dilute hydrochloric acid, water for injections.
Emoxipin Dosage form
Solution for injection.
Basic physical and chemical properties: transparent colorless liquid.
Capillary stabilizing agents.
ATX code C05C X.
Emoxipin® stabilizes the cell membrane, inhibits platelet and neutrophil aggregation, reduces the overall coagulation index, prolongs blood clotting time, reduces blood viscosity, has fibrinolytic activity, increases the content of cyclic nucleotides in tissues, reduces vascular wall permeability. Emoxipin® also has angioprotective properties, protects the retina from damage by high intensity light, improves microcirculation.
Emoxipin® is excreted from the body mainly in the urine and in small amounts – unchanged.
With retrobulbar administration, Emoxipin® appears in the blood almost instantly; during the first 2 hours its concentration decreases sharply and after 24 hours it is absent in the blood. In the tissues of the eye, the concentration of the drug is higher than in the blood.
Subconjunctival and intraocular hemorrhage of various origins.
Angioretinopathy (including diabetic retinopathy).
Central and peripheral choreoretinal dystrophy.
Thrombosis of the central vein of the retina and its branches.
Angiosclerotic macular degeneration (dry form).
Vascular detachment in patients with glaucoma in the postoperative period.
Dystrophic diseases of the cornea.
Injuries, burns of the cornea.
Protection of the cornea (when using contact lenses) and the retina from the effects of high intensity light (sunlight, laser radiation during laser coagulation).
Hypersensitivity to the drug.
Interaction with other medicinal products and other forms of interaction
Adverse events with the use of Emoxipin® on the background of therapy with other drugs have not been described. α-tocopherol acetate potentiates the antioxidant effect of Emoxipin®.